United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2015_register executive 2018-02-26 article Notices D09002ee1c7f71655 D09002ee1c7f716f8 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to Angio360 Diagnostics, LLC, a company having a place of business in Wauwatosa, Wisconsin, to practice the inventions embodied in U.S. Provisional Patent Application No. 60/ 858,068, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed November 9, 2006 (HHS Ref. No.: E- 285-2006/0-US-01); US Provisional Patent Application No. 60/879,457, entitled "Organ And Tumor Associated Endothelial Markers," filed January 8, 2007 (HHS Ref. No. E-285-2006/1-US-01); PCT Application No. PCT/US2007/072395, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 8, 2007 (HHS Ref. No. E-285-2006/2-PCT-01); U.S. Patent Application No. 12/514,297, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed May 8, 2009 (HHS Ref No. E-285-2006/ 2-US-02); Australian Patent No. 2007-317753, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 28, 2007 (HHS Ref No. E-285-2006/2-AU-03); Canadian Patent Application No. 2,669,260, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 28, 2007 (HHS Ref. No. E-285-2006/2-CA-04); U.S. Patent No.: 8,440,411, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed March 21, 2011 (HHS Ref. No. E-285-2006/2-US-05); U.S. Patent Application No. 13/052,878, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed April 16, 2013 (HHS Ref. No.: E-285-2006/2-US-06); and Australian Application Patent No.: 2014-200453, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed January 28, 2014 (HHS Ref No. E-285-2006/2-AU-07). The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Start-Up Exclusive Evaluation Option License Agreement may be worldwide, and the field of use may be limited to "Development of diagnostic tests and kits to determine or monitor pathological angiogenesis related to cancer in animals or humans." Upon the expiration or termination of the Start-up Exclusive Evaluation Option License Agreement, Angio360 Diagnostics, LLC will have the exclusive right to execute a Start-Up Exclusive Patent License Agreement which will supersede and replace the Start-up Exclusive Evaluation Option License Agreement, with no greater field of use and territory than granted in the Start-up Exclusive Evaluation Option License Agreement. 80 FR 57832 https://www.govinfo.gov/app/details/FR-2015-09-25/2015-24331 2015-24331 fr25se15-103 4140-01-P https://www.govinfo.gov/app/details/FR-2015-09-25/2015-24331 https://www.govinfo.gov/content/pkg/FR-2015-09-25/html/2015-24331.htm https://www.govinfo.gov/content/pkg/FR-2015-09-25/pdf/2015-24331.pdf 2 p. 57832 57833 80 FR 57832 Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Development of Diagnostic Tests and Kits for Detection of Pathological Angiogenesis in Cancer; Federal Register Vol. 80, Issue NOTICE 2015-24331 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2015-10-13 4140-01-P 2015-24331 Notice.

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to Angio360 Diagnostics, LLC, a company having a place of business in Wauwatosa, Wisconsin, to practice the inventions embodied in U.S. Provisional Patent Application No. 60/ 858,068, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed November 9, 2006 (HHS Ref. No.: E- 285-2006/0-US-01); US Provisional Patent Application No. 60/879,457, entitled "Organ And Tumor Associated Endothelial Markers," filed January 8, 2007 (HHS Ref. No. E-285-2006/1-US-01); PCT Application No. PCT/US2007/072395, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 8, 2007 (HHS Ref. No. E-285-2006/2-PCT-01); U.S. Patent Application No. 12/514,297, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed May 8, 2009 (HHS Ref No. E-285-2006/ 2-US-02); Australian Patent No. 2007-317753, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 28, 2007 (HHS Ref No. E-285-2006/2-AU-03); Canadian Patent Application No. 2,669,260, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 28, 2007 (HHS Ref. No. E-285-2006/2-CA-04); U.S. Patent No.: 8,440,411, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed March 21, 2011 (HHS Ref. No. E-285-2006/2-US-05); U.S. Patent Application No. 13/052,878, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed April 16, 2013 (HHS Ref. No.: E-285-2006/2-US-06); and Australian Application Patent No.: 2014-200453, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed January 28, 2014 (HHS Ref No. E-285-2006/2-AU-07). The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Start-Up Exclusive Evaluation Option License Agreement may be worldwide, and the field of use may be limited to "Development of diagnostic tests and kits to determine or monitor pathological angiogenesis related to cancer in animals or humans." Upon the expiration or termination of the Start-up Exclusive Evaluation Option License Agreement, Angio360 Diagnostics, LLC will have the exclusive right to execute a Start-Up Exclusive Patent License Agreement which will supersede and replace the Start-up Exclusive Evaluation Option License Agreement, with no greater field of use and territory than granted in the Start-up Exclusive Evaluation Option License Agreement.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 13, 2015 will be considered. Approvals of Start-Up Exclusive Evaluation Option License Agreements: Development of Diagnostic Tests and Kits for Detection of Pathological Angiogenesis in Cancer , rose.freel@nih.gov Vol. 80, no. 186 Office of the Federal Register, National Archives and Records Administration 2015-09-25 continuing daily deposited born digital 510 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2015-09-25 P0b002ee198946c70 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr25se15 https://www.govinfo.gov/app/details/FR-2015-09-25 https://www.govinfo.gov/content/pkg/FR-2015-09-25/pdf/FR-2015-09-25.pdf https://www.govinfo.gov/content/pkg/FR-2015-09-25/xml/FR-2015-09-25.xml fdlp 57693 58194 DGPO 2018-02-26 2024-06-02 FR-2015-09-25 machine generated eng FR FR-2015-09-25 80 186